All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the MDS Hub was pleased to speak to Fernando Barroso Duarte, Hospital Universitário Walter Cantídio, Fortaleza, BR, and Silvia Magalhães, Universidade Federal do Ceará, Fortaleza, BR. We asked, Can the IPSS-R be used as a prognostic tool in HSCT in regions where molecular analysis is unavailable?
Can IPSS-R be used as a prognostic tool in HSCT in regions where molecular analysis is unavailable?
Barroso Duarte begins by discussing a study that enrolled 333 patients across Latin America, and how the IPSS-R affects the overall survival of patients, by comparing low-risk to high-risk patients. Magalhães goes on to mention the difficulty of accessing karyotype analysis in this region, which can affect patient outcomes. Finally, Barroso Duarte summarizes how improving access to cytogenetics will impact survival.
What patient factors should we consider for intermediate- and high-risk patients beyond the IPSS-R score?
The MDS Hub Steering Commitee met on May 5, 2022. The recorded discussion was chaired by Rena Buckstein, and featured Theo de Witte, Silvia...
Practice-changing abstracts in myelodysplastic syndromes
World-leading experts in MDS shared the top abstracts from ASH 2020 that they believed could have the greatest impact on clinical practice.
Subscribe to get the best content related to MDS delivered to your inbox